Oncology

  • 16 January 2020
    Comment

    Assessing recent approvals in bladder cancer

    On December 18 2019, the FDA granted accelerated approval for Seattle Genetic/Astellas Pharmaceutical’s Padcev (enfortumab vedotin-ejfv). Merck and Co’s Keytruda (pembrolizumab) was granted approval for Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle...

  • 15 January 2020
    whitepapers

    Case Study: Bristol-Myers Squibb

    Bristol-Myers Squibb (BMS) is a global biopharmaceutical company headquartered in New York City that specialises in discovering, developing and delivering innovative medicines for patients with serious diseases.

Close
Close
Close

Go Top